1. Cardiovascular mortality and heart failure-related hospitalization were slightly less in the steroidal MRA group, though there was no statistical...

1. Cardiovascular mortality and heart failure-related hospitalization were similar in both groups. 2. There was no statistically significant difference between...

1. Efruxifermin 50 mg once-weekly significantly improved fibrosis at 96 weeks versus placebo. 2. MASH resolution without worsened fibrosis was...

1. The rate of adverse events and seroresponse was similar between groups. 2. There were no incidents of rabies development...

1. Invasive breast cancer recurrence was significantly reduced with extended aromatase inhibitor therapy. 2. No significant reduction was noted for...

1. Progression-free survival and overall survival were significantly greater in the combination therapy group compared to enzalutamide alone. 2. Anemia...

1. The Guselkumab group demonstrated significantly greater clinical and endoscopic responses versus placebo. 2. Serious adverse events were comparable, with...

1. The majority of treatment-related adverse events were mild-to-moderate gastrointestinal events with no reported deaths. 2. Amycretin resulted in significant...

1. Hemoglobin response was significantly greater in the treatment group compared to placebo. 2. Majority of adverse events were mild...

1. The 5-year recurrence-free survival was comparable with ablation and without ablation. 2. Adverse events were comparable in both groups,...